COVID-19 and diabetes mellitus: from pathophysiology to clinical management

S Lim, JH Bae, HS Kwon, MA Nauck - Nature Reviews Endocrinology, 2021 - nature.com
Initial studies found increased severity of coronavirus disease 2019 (COVID-19), caused by
infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in patients …

Immunotherapy: building a bridge to a cure for type 1 diabetes

JA Bluestone, JH Buckner, KC Herold - Science, 2021 - science.org
Type 1 diabetes (T1D) is an autoimmune disease in which T cells attack and destroy the
insulin-producing β cells in the pancreatic islets. Genetic and environmental factors increase …

[HTML][HTML] Baricitinib and β-cell function in patients with new-onset type 1 diabetes

M Waibel, JM Wentworth, M So… - … England Journal of …, 2023 - Mass Medical Soc
Background Janus kinase (JAK) inhibitors, including baricitinib, block cytokine signaling and
are effective disease-modifying treatments for several autoimmune diseases. Whether …

JAK/STAT–emerging players in metabolism

DW Dodington, HR Desai, M Woo - Trends in Endocrinology & Metabolism, 2018 - cell.com
The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is
crucial for transducing signals from a variety of metabolically relevant hormones and …

PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-α and-γ via IRF1 induction

ML Colli, JLE Hill, L Marroquí, J Chaffey… - …, 2018 - thelancet.com
Background Antibodies targeting PD-1 and its ligand PDL1 are used in cancer
immunotherapy but may lead to autoimmune diseases, including type 1 diabetes (T1D). It …

Presumption of innocence for beta cells: why are they vulnerable autoimmune targets in type 1 diabetes?

R Mallone, DL Eizirik - Diabetologia, 2020 - Springer
It is increasingly appreciated that the pathogenic mechanisms of type 1 diabetes involve
both the autoimmune aggressors and their beta cell targets, which engage in a conflicting …

An integrated multi-omics approach identifies the landscape of interferon-α-mediated responses of human pancreatic beta cells

ML Colli, M Ramos-Rodríguez, ES Nakayasu… - Nature …, 2020 - nature.com
Abstract Interferon-α (IFNα), a type I interferon, is expressed in the islets of type 1 diabetic
individuals, and its expression and signaling are regulated by T1D genetic risk variants and …

Gene expression signatures of target tissues in type 1 diabetes, lupus erythematosus, multiple sclerosis, and rheumatoid arthritis

F Szymczak, ML Colli, MJ Mamula, C Evans-Molina… - Science …, 2021 - science.org
Autoimmune diseases are typically studied with a focus on the immune system, and less
attention is paid to responses of target tissues exposed to the immune assault. We presently …

COVID-19: diabetes perspective—pathophysiology and management

S Dallavalasa, SRV Tulimilli, J Prakash… - Pathogens, 2023 - mdpi.com
Recent evidence relating to the impact of COVID-19 on people with diabetes is limited but
continues to emerge. COVID-19 pneumonia is a newly identified illness spreading rapidly …

Inflammation versus regulation: how interferon-gamma contributes to type 1 diabetes pathogenesis

DJ De George, T Ge, B Krishnamurthy… - Frontiers in Cell and …, 2023 - frontiersin.org
Type 1 diabetes is an autoimmune disease with onset from early childhood. The insulin-
producing pancreatic beta cells are destroyed by CD8+ cytotoxic T cells. The disease is …